menu
    • menu
    [{"orgOrder":0,"company":"Cedilla Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cedilla Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedilla Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Cedilla Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Cedilla Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cedilla Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Cedilla Therapeutics \/ Casdin Capital","highestDevelopmentStatusID":"4","companyTruncated":"Cedilla Therapeutics \/ Casdin Capital"},{"orgOrder":0,"company":"Cedilla Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cedilla Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Cedilla Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Cedilla Therapeutics \/ RA Capital Management"}]

    Find Clinical Drug Pipeline Developments & Deals by Cedilla Therapeutics

    Menu

    Cedilla Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cedilla Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Cedilla Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Bayer AG

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bayer to Acquire Exclusive License from Cedilla Therapeutics on Selective Inhibitors in Pre-Clinical Precision...

                            Details : The collaboration strengthens Bayer’s early pipeline in precision oncology by gaining rights to develop and commercialize Cedilla’s CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 01, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Bayer AG

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cedilla Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Cedilla Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $82.6 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Cedilla Therapeutics Completes $82.6M Series B Financing

                            Details : Proceeds from the financing will support Cedilla’s continued growth and development of its two lead programs, an inhibitor of TEAD for the treatment of solid tumors, and a highly selective inhibitor of CDK2/Cyclin E for the treatment of multiple tumors...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 25, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $82.6 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cedilla Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Cedilla Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Casdin Capital

                            Deal Size : $57.6 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Cedilla Therapeutics Announces $57.6 Million Series B Financing

                            Details : Proceeds from this financing will support ongoing efforts to build a broad portfolio of small molecule medicines, including the identification and preclinical development of Cedilla’s first two product candidates.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 13, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Casdin Capital

                            Deal Size : $57.6 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth